Atrial fibrillation related to ibrutinib treatment can be managed with standard measures and DOACs without patients having to stop cancer treatment, experience at an Australian centre suggests. Ibrutinib-related AF was more common in real world practice than in the literature, according to a small cohort report by haematologists at the Hunter New England Health District. ...
Already a member?
Enter your email to keep reading.